Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

Also called NCT03304821

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 114 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03304821
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03304821. Randomized; double masking; primary purpose treatment. Start 2017-12-19 (actual); primary completion 2025-07-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
Acronym
GPAD-3
Condition
Peripheral Artery Disease (PAD)
Intervention (Drug)
GM-CSF
Intervention (Drug)
Placebo
Lead sponsor
Emory University (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct03304821
Content hash
b5e2714f8ff9383605e2a70148e2188d9e5e82fc15f5436d586c7448232fa4f0